Drug
Cep 26401
Cep 26401: highest development phase Phase 1, developed by Teva. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Teva
Trials
| Drug | Phase | Indication |
|---|---|---|
| CEP-26401 NCT01903824 | Phase 1 | Cognitive Impairment |
Latest
No recent events.
Follow Cep 26401 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.